

# Self-Checking Cell-Based Assays for GPCR Desensitization and Resensitization

Journal of Biomolecular Screening  
1–7  
© 2014 Society for Laboratory  
Automation and Screening  
DOI: 10.1177/1087057114534299  
jbx.sagepub.com  


Gregory W. Fisher<sup>1</sup>, Margaret H. Fuhrman<sup>1</sup>, Sally A. Adler<sup>1</sup>,  
Christopher Szent-Gyorgyi<sup>1</sup>, Alan S. Waggoner<sup>1</sup>, and  
Jonathan W. Jarvik<sup>1</sup>

## Abstract

G protein-coupled receptors (GPCRs) play stimulatory or modulatory roles in numerous physiological states and processes, including growth and development, vision, taste and olfaction, behavior and learning, emotion and mood, inflammation, and autonomic functions such as blood pressure, heart rate, and digestion. GPCRs constitute the largest protein superfamily in the human and are the largest target class for prescription drugs, yet most are poorly characterized, and of the more than 350 nonolfactory human GPCRs, over 100 are orphans for which no endogenous ligand has yet been convincingly identified. We here describe new live-cell assays that use recombinant GPCRs to quantify two general features of GPCR cell biology—receptor desensitization and resensitization. The assays employ a fluorogen-activating protein (FAP) reporter that reversibly complexes with either of two soluble organic molecules (fluorogens) whose fluorescence is strongly enhanced when complexed with the FAP. Both assays require no wash or cleanup steps and are readily performed in microwell plates, making them adaptable to high-throughput drug discovery applications.

## Keywords

G protein-coupled receptors, GPCRs, cell based assays, receptor desensitization, receptor resensitization

## Introduction

Assays that detect molecular events triggered by ligand binding to particular G protein-coupled receptors (GPCRs) (e.g., activation/inhibition of adenylyl cyclases or phospholipases, or mobilization of  $\beta$ -arrestin) have been a mainstay of GPCR drug discovery for many years.<sup>1</sup> However, when one is screening for agonists to orphan receptors<sup>2</sup> or screening for biased or allosteric ligands to nonorphan receptors,<sup>3,4</sup> one may not know with confidence what event(s) to screen for. In such cases, assays that are directed to a common feature of GPCR biology, rather than to a specific signaling pathway, may be more productive.

Following stimulation with agonists, almost all GPCRs exhibit receptor desensitization, during which receptor molecules are internalized by endocytosis over a period of minutes or tens of minutes. When agonist is removed, resensitization ensues, during which some or all of the internalized receptors may return to the surface by exocytosis, again over a period of minutes. Since receptor desensitization and resensitization are general features of GPCR biology, assays that directly measure these processes present opportunities to uncover responses that standard approaches might miss, for example, heterologous desensitization<sup>5</sup> through another receptor. The drug discovery opportunity may be particularly strong when resensitization

is measured, since high-throughput screens for molecules that directly affect resensitization have not been available.

In previous work, we described the application of fluorogen-activating proteins (FAPs)<sup>6</sup> to assays that address receptor downregulation by measuring either changes in surface receptor abundance (surface signal depletion assay) or internalized receptor abundance (internal signal accumulation assay).<sup>7</sup> Here we describe a related new assay system that concomitantly measures receptor loss from the surface and receptor accumulation inside the cell. This system represents an improvement over previous systems for two primary reasons: (1) it is intrinsically self-checking, since in the absence of artifact, receptor loss and receptor accumulation will be

<sup>1</sup>Department of Biological Sciences and Molecular Biosensor and Imaging Center, Carnegie Mellon University, Pittsburgh, PA, USA

Received Jan 31, 2014, and in revised form Mar 28, 2014. Accepted for publication Apr 9, 2014.

Supplementary material for this article is available on the *Journal of Biomolecular Screening* Web site at <http://jbx.sagepub.com/supplemental>.

## Corresponding Author:

Jonathan W. Jarvik, Department of Biological Sciences and Molecular Biosensor and Imaging Center, Carnegie Mellon University, 4400 Fifth Ave, Pittsburgh, PA 15213, USA.  
Email: jarvik@cmu.edu

reciprocally related, and (2) it provides a straightforward means to measure receptor resensitization as well as desensitization.

## Materials and Methods

### FAPs, Fluorogens, and GPCR Ligands

The fluorogen-activating protein used in this study was the single-chain antibody (scFv) HL1.0.1-TO1.<sup>6</sup> The fluorogens used in this study were the membrane-impermeant molecules TO1-2p<sup>6</sup> and TO1-2p-Cy5, both derivatives of thiazole orange.

(-)-Isoproterenol(+)-bitartrate, DL-Propranolol HCL epinephrine, and nor-epinephrine were from Sigma-Aldrich (St. Louis, MO). Recombinant CXCL12/SDF-1a and AMD 3100 octahydrochloride were from R&D Systems (Minneapolis, MN).

### Mammalian Cell Culture Conditions

U937 cells were grown at 37 °C, 5% CO<sub>2</sub> in RPMI 1640 plus 10% heat-inactivated fetal calf serum (FCS), 100 U/mL penicillin, and 100 mg/mL streptomycin. HEK cells were grown under the same conditions in Dulbecco's modified Eagle's medium (DMEM) plus FCS, 100 U/mL penicillin, and 100 mg/mL streptomycin. All experiments were performed on cells in their culture medium under their natural growing conditions. Periodically, cell lines were sorted to maintain them at greater than 95% positive for the FAP-tagged GPCR.

### Fluorescence Microscopy

For confocal microscopy, cells were imaged on 23-mm glass-bottom dishes (part no. p35G-1.5-14-C; Mattek, Ashland, MA) using either a Zeiss LSM510 META confocal laser scanning microscope (Carl Zeiss, Thornwood, NY) equipped with a 525/50-nm band pass filter (TO1-2p) and a 680/60-nm band pass filter (TO1-2p-Cy5) or an Andor confocal microscope (Andor, Belfast, Northern Ireland) equipped with a 63×, 1.47 NA objective. For both systems, an argon 488-nm laser was used to excite TO1-2p and TO1-2p-Cy5 (via energy transfer). In some experiments, the Cy5 moiety was directly excited with the 623-nm HeNe laser. Emission filters were standard fluorescein (533 nm) and Cy5 (685 nm) emission filters. Growing conditions were maintained on the microscope stage using a 37 °C, 5% CO<sub>2</sub>, constant humidity specimen chamber (LiveCell; Pathology Devices, Westminster, MD).

For 20× nonconfocal microscopy, imaging was performed using an Olympus IX50 microscope equipped with an HBO 100-watt light source with appropriate filters (TO1-2p HQ470/40ex and HQ500LPem; TO1-2p-Cy5

HQ620/60 ex and HQ700/75em; Chroma Technologies, Bellows Falls, VT) and thermoelectric stage heater (20/20 Technology, Wilmington NC). Images were acquired using a Photometrics CoolSnap HQ CCD camera (Photometrics, Tucson, AZ). Illumination intensity and gain settings on the microscope were held constant for all observations. Because there was variation in illumination intensity across the image fields, cell masks were made using ImageJ (National Institutes of Health, Bethesda, MD) and the masks applied to adjacent cell-free regions in each field. The mean pixel intensity for each cell and its respective background means were tabulated and subtracted from each other, and these values were averaged for 35 cells.


### Flow Cytometry

Cells were analyzed using a Becton Dickinson (BD) FACS Vantage SE Flow Cytometer with FACS Diva option (Becton Dickinson, Franklin Lakes, NJ). An argon 488-nm laser was used to excite TO1-2p and TO1-2p-Cy5 (via energy transfer). Emission filters were 530/30 and 695/40 nm, respectively. Quantitation was carried out using BD software with compensation. Primary data points were mean intensity values for 2500 cells. Plots were generated in Excel (Microsoft, Seattle, WA) and replotted in GraphPad Prism (GraphPad Software, San Diego, CA) using single-phase exponential and sigmoidal curve fits as appropriate. EC<sub>50</sub> values were generated in GraphPad Prism from the same data. All experiments were repeated several times with nearly identical results. The peaks in the fluorescence-intensity histograms were similar in aspect to those shown in Fisher et al.<sup>7</sup>

## Results and Discussion

All receptors used in this study were tagged at their extracellular N-termini with FAP HL1.0.1-TO1 as previously described<sup>7</sup> and were expressed in U937 cells (a nonadherent human lymphoma line) and HEK 293 cells (an adherent human embryonic kidney cell line). Two membrane-impermeant fluorogens specific to HL1.0.1-TO1 were used (**Fig. 1A**), TO1-2p ("exchange fluorogen") and TO1-2p-Cy5 ("pulse fluorogen"). When bound to the FAP and excited by an argon gas laser (488- and 514-nm lines), the exchange fluorogen emits in the green (530 nm). With the same excitation, the pulse fluorogen emits in the far red (670 nm) due to energy transfer from the TO1 moiety to the Cy5 moiety.

When incubated with pulse fluorogen, cells expressing FAP-tagged receptors rapidly acquire red fluorescence, with signal confined to the cell surface due to the membrane-impermeant nature of the fluorogen. Titration experiments with FAP-tagged U937 cells showed that maximal signal intensity is obtained with 5 nM or greater concentrations of



**Figure 1.** Rapid exchange of TO1-2p for TO1-2p-Cy5 at the cell surface. **(A)** Structures and properties of TO1-2p and TO1-2p-Cy5 fluorogens. **(B)** Schematic representation of fluorogen exchange upon addition of exchange fluorogen to cells preincubated with pulse fluorogen. **(C)** Upper panel: superimposed DIC and fluorescence micrographs of two U937 cells expressing membrane-anchored HLI.0.1-TO1 FAP taken at ~12-s intervals. Cells were preincubated with 5 nM TO1-2p-Cy5 for ~5 min; at the time indicated by the arrow, 350 nM TO1-2p was added. Lower panel: flow cytometric data for cells treated as above.


fluorogen. When excess exchange fluorogen is added, the exchange fluorogen displaces the pulse fluorogen by mass action, and the surface fluorescence changes from red to green (**Fig. 1B**). To drive the exchange rapidly, we used 350 nM exchange fluorogen—a concentration more than 100-fold above the  $K_d$  for the FAP. With this protocol, displacement of the pulse fluorogen reached completion in less than a minute (**Fig. 1C**), yet there was no spurious signal from fluorogen in solution because the exchange fluorogen exhibits essentially no fluorescence except when bound to the FAP.

We chose four human GPCRs for assay development and validation: the adrenergic receptors  $\alpha 2A$ ,  $\beta 1$ , and  $\beta 2$  (encoded by the genes *ADRA2A*, *ADRB1*, and *ADRB2*) and the chemokine receptor C-X-C type 4 (encoded by the gene *CXCR4*). Recombinant genes encoding each receptor with the HLI.0.1-TO1 FAP at the N-terminus were stably expressed in U937 and HEK 293 cells.

To quantify agonist-stimulated receptor internalization, we developed simple kinetic and dose-response protocols that

take advantage of the membrane-impermeant nature of the two fluorogens. Cells are incubated with agonist at a fixed concentration for a variety of times, or at a range of concentrations for a fixed period. Pulse fluorogen is added at the beginning of each incubation and exchange fluorogen is added at the end, and signal in the red and green channels is measured shortly thereafter. The protocols thus have the following steps: (1) add pulse fluorogen plus agonist, (2) allow time for response, (3) add exchange fluorogen, and (4) measure fluorescent signal. Note that when exchange fluorogen is added at step 3, exchange is expected to occur for all receptor molecules at the cell surface, resulting in a change in surface color from red to green. No exchange is expected for receptor molecules that were internalized in response to agonist because the fluorogens are membrane impermeant. Thus, the red signal should provide a quantitative measure of internalized receptor and the green signal a quantitative measure of uninternalized receptor.

For CXCR4, we used the natural polypeptide agonist CXCL12, also known as SDF-1. For each of the three adrenergic receptors, we used the natural catecholamine




**Figure 2.** Agonist-stimulated desensitization. **(A)** Upper two panels show time course for receptor internalization. U937 cells expressing fluorogen-activating protein (FAP)-tagged human  $\beta$ 2AR or CXCR4 were incubated with pulse fluorogen plus 10  $\mu$ M agonist (isoproterenol or CXCL12). At the indicated times, exchange fluorogen was added, and fluorescence in both channels was measured by flow cytometry within the next 2 to 15 min. Lower two panels show dose response for receptor internalization. U937 cells expressing FAP-tagged  $\beta$ 2AR or CXCR4 were incubated for 40 min with pulse fluorogen plus agonist (isoproterenol or CXCL12) at a range of concentrations, after which exchange fluorogen was added and fluorescence in both channels was measured by flow cytometry within the next 2 to 3 min.  $EC_{50}$  for isoproterenol on  $\beta$ 2AR was 0.26  $\mu$ M in the red channel and 0.26  $\mu$ M in the green channel;  $EC_{50}$  for CXCL12 on CXCR4 was 1.7 nM in the red channel and 0.69 nM in the green channel. **(B)** Dose-response data obtained as described above for the human  $\alpha$ 2A,  $\beta$ 1, and  $\beta$ 2 adrenergic receptors stimulated with epinephrine, nor-epinephrine and isoproterenol.  $EC_{50}$  values are given in **Supplemental Table S1**. **(C)** Confocal fluorescence micrographs of U937 and HEK 293 cells expressing FAP-tagged human  $\beta$ 2AR and CXCR4. In each set of three micrographs, the left-hand image is of cells exposed to pulse fluorogen alone, the center image is of cells exposed to agonist plus pulse fluorogen for 40 min, and the right-hand image is of cells exposed to agonist plus pulse fluorogen for 40 min followed by exchange fluorogen for approximately 2 min.

agonists epinephrine and norepinephrine and the synthetic agonist isoproterenol. Data were collected two ways: by flow cytometry and by confocal microscopy.

Flow cytometric data from representative experiments are plotted in **Figure 2A,B**. The curves show a simple reciprocal relationship: when exchange fluorogen signal (green, representing surface receptor) goes down, pulse fluorogen signal (red, representing internalized receptor) goes up. Accordingly, the point at which the curves cross represents the  $ET_{50}$  or  $EC_{50}$  values for the particular receptor/agonist pair. The  $EC_{50}$  values for CXCL12 on CXCR4 in these experiments were similar to what has been reported for other cell-based assays that measure second messengers or other downstream events, but the  $EC_{50}$ s for the adrenergic receptor agonists (see legend to **Fig. 2** and **Suppl. Table S1**) were somewhat higher than have been reported for other

cell-based assays, as we observed previously for FAP-tagged  $\beta$ 2AR.<sup>7</sup> This may be a consequence of the fact that the  $EC_{50}$ s that we obtain represent half-maximal values for receptor internalization or surface retention, not half-maximal signaling per se. It is important to note, however, that the rank order of response to the three different agonists reflects the well-established rank order of selectivity for each of the three adrenergic receptors against which they were tested.

Representative confocal micrographs for CXCL12-stimulated CXCR4 cells and for isoproterenol-stimulated  $\beta$ 2AR cells are shown in **Figure 2C**. The postexchange images (panels labeled “pulse/exchange w agonist”) show clearly that the pulse fluorogen signal represents internalized receptor and the exchange fluorogen signal represents surface receptor.



**Figure 3.** Antagonist-stimulated desensitization-inhibition and resensitization. **(A)** U937 cells expressing fluorogen-activating protein (FAP)-tagged  $\beta$ 2AR or CXCR4 were incubated for 40 min with pulse fluorogen plus 10  $\mu$ M agonist (epinephrine or CXCL12) plus antagonist (propranolol or AMD 3100) at a range of concentrations; exchange fluorogen was then added, and fluorescence in both channels was measured by flow cytometry within the next 2 to 3 min. The scales at the right of each plot show the raw mean photocount values from the flow analysis.  $EC_{50}$  for propranolol was 18 nM in the red channel and 24 nM in the green;  $EC_{50}$  for AMD 3100 was 9.6 nM in the red channel and 5.4 nM in the green. **(B)** U937 cells expressing FAP-tagged  $\beta$ 2AR or CXCR4 were incubated for 40 min with pulse fluorogen plus 10  $\mu$ M agonist (epinephrine or CXCL12); antagonist (propranolol or AMD 3100) was then added at a range of concentrations, and 40 min later, exchange fluorogen was added and fluorescence in both channels was measured by flow cytometry within the next 2 to 3 min.  $EC_{50}$  for propranolol was 17 nM in the red channel and 20 nM in the green;  $EC_{50}$  for AMD 3100 was 4.8 nM in the red channel and 7.1 nM in the green. **(C)** U937 cells expressing FAP-tagged human  $\beta$ 2AR exposed to isoproterenol and pulse fluorogen followed by 2 min in exchange fluorogen (left micrograph, no resensitization) or exposed to agonist and pulse fluorogen and then 10  $\mu$ M propranolol for 30 min, then 2 min in exchange fluorogen (right micrograph, resensitization).


To measure antagonist activity, we modified the protocol to quantify inhibition of agonist-stimulated receptor internalization—a classic measure of antagonist activity. Cells were treated for a fixed period with a known agonist at a constant concentration along with antagonist at a range of concentrations. Then, 5 nM pulse fluorogen was added at the beginning of each incubation, and 350 nM exchange fluorogen was added at the end. The antagonist dose-response protocol thus has the following steps: (1) add pulse fluorogen plus agonist and antagonist, (2) allow time for response, (3) add exchange fluorogen, and (4) measure fluorescent signal.

Flow cytometric data for dose-response experiments of this kind are plotted in **Figure 3A** for inhibition of epinephrine-stimulated  $\beta$ 2AR internalization by the  $\beta$ -adrenergic receptor antagonist propranolol and for inhibition of CXCL12-stimulated CXCR4 internalization by the

antagonist AMD 3100. Additional experiments (not shown) showed that propranolol also inhibited internalization of the  $\beta$ 1 receptor but was ineffective in inhibiting  $\alpha$ 2A receptor internalization, reflecting the known selectivity of propranolol for these receptors.

In addition to measuring classic antagonist activity as described above, we also developed a protocol to detect and quantify receptor resensitization. In these experiments, cells were desensitized with agonist and then treated with antagonist at a variety of concentrations. The protocol has the following steps: (1) add pulse fluorogen plus agonist, (2) allow time for response, (3) add antagonist, (4) allow time for response, (5) add exchange fluorogen, and (6) measure fluorescent signal.

Experiments in which cells expressing the adrenergic receptors were exposed to epinephrine for 40 min followed by addition of propranolol showed the return of



**Figure 4.** Time course of desensitization quantified by fluorescence microscopy at 20 $\times$ . U937 cells expressing fluorogen-activating protein (FAP)-tagged  $\beta$ 2AR were incubated with 5 nM pulse fluorogen and 20  $\mu$ M isoproterenol for the indicated times, and then 350 nM exchange fluorogen was added and images were acquired and analyzed as described under Materials and Methods. **(A)** Representative image in exchange fluorogen channel at the 0-min time point. **(B)** Representative image in pulse fluorogen channel at the 20-min time point. **(C)** Graphical representation showing fraction of total signal in each channel at each time point.

most previously internalized receptors to the surface with dose-response properties indistinguishable from those obtained in the desensitization assay (Fig. 3B, left panel). Similar resensitization experiments with CXCR4 gave somewhat different results (Fig. 3B, right panel); antagonist addition did *not* result in redistribution of already internalized receptors to the surface, although it did prevent internalization of receptor molecules that were still at the surface with the same dose-response values as in the desensitization assay. This is evident from inspection of the raw photocount values shown at the right of each graph. Figure 3C shows representative micrographs of non-resensitized (left panel) and resensitized (right panel)  $\beta$ 2AR cells.

Finally, we used low-resolution fluorescence microscopy to show that the fluorogen exchange system is suitable for high-throughput analysis by imaging cytometry. U937 cells expressing FAP-tagged  $\beta$ 2AR were subjected to the desensitization time-course protocol described previously, and fluorescence images in the red and green channels were acquired using a 20 $\times$  low numerical-aperture air objective. Robust results were obtained from the analysis of a small number of cells (35) at each time point (Fig. 4), indicating that the assays are well suited for automated data collection and analysis using currently available imaging cytometry systems.

A unique feature of the assays described here is that they are intrinsically self-checking: in the desensitization assay, signal from the pulse fluorogen goes up and signal from the exchange fluorogen goes down equivalently, and in the resensitization assay, signal from the exchange fluorogen goes up and signal from the pulse fluorogen goes down, again equivalently. This reciprocity gives the assays a self-checking quality (i.e., if reciprocity is not observed for a given compound, an off-target effect is likely). Reciprocity

also means that relatively small effects, as expected for certain partial agonists, for example, may be taken seriously if both signals change in concert, whereas the equivalent small effect in a single-dimension assay might appear to be without significance. We note that if the internalized receptor is degraded at longer times,<sup>8</sup> this will be reflected in a reduction of the pulse fluorogen signal, an assay output that could be used to quantify receptor lifetime.

We and colleagues recently described a related single-color FAP-based assay for loss of receptor at the cell surface<sup>7</sup> that has been applied to a number of screens against GPCRs using high-throughput flow cytometry,<sup>9,10</sup> including a screen of approximately 350,000 compounds against the human  $\beta$ 2 adrenergic receptor.<sup>11</sup> In addition to bona fide agonists, the screen identified a number of compounds that reduce surface signal not by stimulating the receptor but by inhibiting fluorogen activation by the FAP. These compounds are interesting in their own right, but in the context of drug screening, they represent undesired false-positive hits. With the fluorogen exchange assay, such compounds would not be scored as hits in the primary screen due to absence of reciprocity.

The assays described here can be applied to any receptor whose biology includes desensitization, irrespective of whether the desensitization mechanism is known and irrespective of whether the receptor is well characterized or is an orphan. Not only might new agonists, reverse agonists, and antagonists be discovered in this way, but the system offers opportunities to discover molecules that potentiate or inhibit receptor internalization or recycling *independent* of signaling—molecules that are likely to be missed by standard approaches. Such molecules would be expected to alter the sensitivity and/or the intensity of the response governed by the receptor on a time scale measured in tens of

minutes or longer, and as such they might represent new classes of drugs to be used in combination with known drugs or by themselves.

### Acknowledgments

We thank Brigitte Schmitt for the synthesis of TO1-2p-Cy5, Yehuda Creeger for assistance with flow cytometry, and Haibing Teng for assistance with confocal microscopy.

### Declaration of Conflicting Interests

The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: CS-G and ASW are shareholders in Sharp Edge Labs Inc, and JWJ is a shareholder in SpectraGenetics Inc. Both companies have licensed certain rights to the FAP technology from Carnegie Mellon University.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grant U54 GM103529 from the National Institute of General Medical Sciences, National Institutes of Health.

### References

1. Zhang, R.; Xie, X. Tools for GPCR Research. *Acta Pharmacol. Sinica* **2012**, *33*, 372–384.
2. Civelli, O.; Reinscheid, R. K.; Zhang, Y.; et al. G Protein–Coupled Receptor Deorphanizations. *Annu. Rev. Pharmacol. Toxicol.* **2013**, *53*, 127–146.
3. Digby, G. J.; Conn, P. J.; Lindsley, C. W. Orthosteric and Allosteric Induced Ligand Directed Trafficking at GPCRs. *Curr. Opin. Drug Discov. Dev.* **2010**, *13*, 587–594.
4. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 1–13.
5. Kelly, E.; Bailey, C. P.; Henderson, G. Agonist-Selective Mechanisms of GPCR Desensitization. *Br. J. Pharmacol.* **2008**, *153*, S379–S388.
6. Szent-Gyorgyi, C.; Schmitt, B. A.; Creeger, Y.; et al. Fluorogen-Activating Single-Chain Antibodies for Imaging Cell Surface Proteins. *Nat. Biotechnol.* **2008**, *26*, 235–240.
7. Fisher, G. W.; Adler, S. A.; Fuhrman, M. H.; et al. Detection and Quantification of B2AR Internalization in Living Cells Using FAP-Based Biosensor Technology. *J. Biomol. Screen.* **2010**, *15*, 703–709.
8. Cottrell, G. S. Roles of Proteolysis in Regulation of GPCR Function. *Br. J. Pharmacol.* **2013**, *168*, 576–590.
9. Wu, Y.; Tapia, P. H.; Fisher, G. W.; et al. Discovery of Regulators of Receptor Internalization by High Throughput Flow Cytometry. *Mol. Pharmacol.* **2012**, *82*, 645–657.
10. Wu, Y.; Tapia, P. H.; Fisher, G. W.; et al. High Throughput Flow Cytometry Compatible Biosensor Based on Fluorogen Activating Protein Technology. *Cytometry A* **2013**, *83*, 220–226.
11. Wu, Y.; Tapia, P. H.; Gouveia, K.; et al. *Inhibitors of FAP-Fluorogen Interaction as a Multiplex Assay Tool Compound for Receptor Internalization Assays. Probe Reports from the NIH Molecular Libraries Program*; National Center for Biotechnology Information: Bethesda, MD, **2013**.